The White House says aligning U.S. drug prices with global rates may slash costs—but experts remain divided. What the $529 Billion Savings Really Means According to White House economists, Trump’s drug pricing strategy—often called the “most favored nation” model—could reduce prescription drug costs by up to $529 billion over 10 years. The idea is simple: Americans s

GLP-1 Drugs Drive Pharma Growth GLP-1 weight loss drugs are powering a sharp rebound in pharma R&D returns, but analysts warn the boom may be creating a risky “bubble effect” across the sector. According to Deloitte’s latest pharma innovation analysis, R&D returns among the world’s top 20 drugmakers have climbed to 7%, driven largely by obesity and diabetes treatments such as GLP-1 drugs. Obesity Drugs Overtake Oncology

A newly announced policy introducing tariffs on certain imported pharmaceuticals could gradually increase prescription drug costs for patients across the United States. The measure applies primarily to brand-name medications that remain under patent, along with some of their active ingredients, with tariff rates potentially reaching up to 100 percent depending on compliance with pricing or domestic production conditions. While generic medications and biosimilars are currently exclud

​REDWOOD CITY, California — Revolution Medicines announced positive results from a late-stage clinical trial evaluating its experimental drug daraxonrasib, showing a significant survival benefit for patients with advanced pancreatic cancer who had previously undergone treatment. According to the company, patients receiving the once-daily oral therapy lived a median of 13.2 months, compar

A California-based pharmaceutical company has expa

President Donald Trump’s recently announced agreements with pharmaceutical companies are expected to have a limited effect on what most Americans pay for prescription drugs, according to health policy experts who say the scope and structure of the deals leave many patients unaffected. Since Sept. 30, the Trump administration has reached agreements with 14 drugmakers in exchange for relie

Eli Lilly reached a historic milestone on Friday when it briefly surpassed a $1 trillion market capitalization, becoming the first health-care company in the world to enter a territory long dominated by technology giants. The company’s stock hovered near $1,048 per share during morning trading, touching the trillion-dollar threshold before pulling back slightly. It is only the second nontechnology business in the United States to reach this valuation, following Berkshire Hathaway’s climb

A senior pharmaceutical executive collapsed during an Oval Office event where former U.S. President Donald Trump was announcing a new initiative to reduce the prices of obesity drugs. The incident caused a sudden interruption to the live broadcast of the announcement, which was centered on a major agreement between the Trump administration and leading pharmaceutical manufacturers. According to eyewitnesses, the executive, later identified as Gordon Findlay of Novo Nordisk, lost his

Washington: US President Donald Trump has announced sweeping new tariffs on imported pharmaceutical products, a move that could trigger widespread consequences for the global drug trade and India’s pharmaceutical sector in particular. Effective October 1, 2025, Washington will impose tariffs of up to 100 percent on branded and patented pharmaceutical drugs unless the manufacturing companies are building their production facilities within the United States. The president emphasized that

Walmart has confirmed that its Neighborhood Market at 3112 Santa Rita Road will close on October 2. The store’s pharmacy will also shut down on the same date. Walmart spokesperson Anne Hatfield did not give a specific reason for the closure, but noted there are three Walmart locations within eight miles of the Pleasanton market including a full-service Walmart in Livermore and a newly remodeled Neighborhood Marke

A major industrial tragedy struck Hyderabad on the morning of June 30, 2025, when a powerful explosion ripped through a pharmaceutical manufacturing unit at Sigachi Industries Pvt. Ltd. in the Pashamylaram industrial area. The blast, which reportedly occurred due to a pressure build-up in one of the reactors, has claimed the lives of eight workers and left 13 others injured and trapped under the debris. Firefighters rushed to the scene following a distress cal

Rite Aid, the once-prominent national pharmacy chain now navigating Chapter 11 bankruptcy, is preparing to shutter 56 additional store locations across California, bringing the total number of confirmed closures in the state to 235 by 2025. As part of its ongoing financial restructuring efforts, the company is systematically downsizing its retail footprint, with California emerging as one of the hardest-hit states in this process. The latest wave of closures reflects the pharmacy chain’

Several over-the-counter eye products have been voluntarily recalled following a U.S. Food and Drug Administration audit that uncovered issues related to manufacturing practices. The recall, issued by AvKARE, involves Artificial Tears Ophthalmic Solution, a commonly used product for treating dry or irritated eyes. According to the recall announcement posted by the company, the products were pulled due to deviations in manufacturing that may have compromised quality and potentially pose a risk

Pharmacy giant Rite Aid could close every remaining store in California after filing for bankruptcy for a second time last week. The company recently confirmed plans to shutter all locations and distribution centers across the country over the next several months. A representative from the drugstore chain stated that this includes the possibility of closing all 347 stores currently operating in California, with at least 15 of those in the Bay Area at risk if they are not sold or transferred to n

Torrent Pharmaceuticals Ltd. will hold a meeting on January 24 to consider the payment of an interim dividend for the financial year 2024-25. The company has set February 1 as the record date for determining the eligible members for the dividend payment, if declared. The interim dividend will be for the equity shares of Rs 5 each. Earlier, Samir Mehta, President of the Indian Pharmaceutical Alliance and Chairperson of Torrent Group, highlighted the industry's plans to grow signi

Jefferies predicts that 2025 will be a year of reckoning for Contract Development and Manufacturing Organization (CDMO) stocks, where actual earnings performance will determine the sector’s winners and laggards. While CDMO stocks saw remarkable returns in 2024, ranging from 20% to 80%, the brokerage points out that earnings were mixed, with some companies seeing upgrades, while others experienced sharp downgrades. Despite this, investor confidence remains strong, driven by long-term opt

In 2025, the Indian pharmaceutical industry is set for a profound transformation driven by innovation, research excellence, and expanded global access. With the industry projected to reach USD 130 billion by 2030, India aims to become a global hub for high-quality, affordable pharmaceuticals, focusing on areas like CAR-T cell therapy, mRNA vaccines, and biosimilars. Technological advancements like AI, machine learning, and precision medicine are expected to revolutionize drug discovery, manuf

A tragic incident occurred in Odisha's Mayurbhanj district when a Class 10 student, Sukhdev Munda, died after allegedly being administered a wrong injection at a local pharmacy. Sukhdev, who was suffering from a skin infection, was taken to Sarbeswar Medicines pharmacy in Saharpada Market by his father for treatment. The pharmacist assured them that an injection would provide quick relief. However, shortly after receiving the injection, Sukhdev's condition deteriorated, and he passed

Bharat Rashtra Samithi (BRS) working president K. T. Rama Rao (KTR) has leveled serious allegations against Chief Minister A. Revanth Reddy, accusing him of forcefully acquiring land from farmers in Kodangal for a Pharma Village project. The land, according to KTR, is intended for Maxbien Pharma, a company owned by Revanth Reddy’s son-in-law. KTR condemned the Chief Minister for prioritizing his family's interests over the welfare of the farmers and accused him of using coercive tac